Xilio Therapeutics, Inc. (XLO) Q4 2024 Annual Earnings
XLO·Reported March 11, 2025·Before market open
Xilio Therapeutics, Inc. reported Q4 2024 revenue of $1.7M, missed analyst consensus of $23.2M by $21.5M. Diluted EPS came in at $-0.20, beat the $-3.03 consensus by $2.83.
Revenue
$1.7Mmissed by $21.5M
Consensus: $23.2MDiluted EPS
$-0.20beat by $2.83
Consensus: $-3.03
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Xilio Therapeutics, Inc.'s Q4 2024 earnings report.
Xilio Therapeutics, Inc. (XLO) reported Q4 2024 earnings on March 11, 2025 before market open.
Xilio Therapeutics, Inc. reported revenue of $1.7M and diluted EPS of $-0.20 for Q4 2024.
Revenue missed the consensus estimate of $23.2M by $21.5M. EPS beat the consensus estimate of $-3.03 by $2.83.
You can read the 10-K periodic report (0001558370-25-002640) directly on SEC EDGAR. The filing index links above go to sec.gov.